Parion Sciences, Inc. announced that its partner, Gilead Sciences (Nasdaq: GILD), has initiated a Phase I clinical trial of GS9411 in healthy volunteers to evaluate the safety and tolerability of the investigational compound. GS9411 is designed to increase airway hydration for the treatment of pulmonary disease.
[Sadece Üyeler Görebilir. Üye olmak için tiklayiniz...]
Parion Sciences Announces Initiation Of Phase I Clinical Trial To Evaluate Safety And Tolerability O
Normal Mod
